Unleashing Cancer Cells on Surfaces Exposing Motogenic IGDQ Peptides
Source abstract
Abstract
Thiolated peptides bearing the Ile‐Gly‐Asp (IGD) motif, a highly conserved sequence of fibronectin, are used for the preparation of anisotropic self‐assembled monolayers (SAM gradients) to study the whole‐population migratory behavior of metastatic breast cancer cells (MDA‐MB‐231 cells). Ile‐Gly‐Asp‐Gln‐(IGDQ)‐exposing SAMs sustain the adhesion of MDA‐MB‐231 cells by triggering focal adhesion kinase phosphorylation, similarly to the analogous Gly‐Arg‐Gly‐Asp‐(GRGD)‐terminating surfaces. However, the biological responses of different cell lines interfaced with the SAM gradients show that only those exposing the IGDQ sequence induce significant migration of MDA‐MB‐231 cells. In particular, the observed migratory behavior suggests the presence of cell subpopulations associated with a “stationary” or a “migratory” phenotype, the latter determining a considerable cell migration at the sub‐cm length scale. These findings are of great importance as they suggest for the first time an active role of biological surfaces exposing the IGD motif in the multicomponent orchestration of cellular signaling involved in the metastatic progression.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cell Adhesion Molecules Research · Monoclonal and Polyclonal Antibodies Research · Cellular Mechanics and Interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Namur Research College (NARC) and Department of Chemistry University of Namur (UNamur) Rue de Bruxelles 61 5000 Namur Belgium
Department of Chemical and Pharmaceutical Sciences INSTM UdR Trieste University of Trieste P.le Europa 1 34127 Trieste Italy
Cellular Biology Research Unit—NARILIS University of Namur (UNamur) Rue de Bruxelles 61 5000 Namur Belgium
References (71)
Show source-provided references
1. 10.1126/science.109205310.1126/science.1092053 ↗
2. 10.1038/nrc107510.1038/nrc1075 ↗
3. 10.1016/S0092-8674(00)81280-510.1016/S0092-8674(00)81280-5 ↗
4. 10.1073/pnas.040895410210.1073/pnas.0408954102 ↗
5. 10.1038/nphys130610.1038/nphys1306 ↗
6. 10.1038/nrm272010.1038/nrm2720 ↗
7. Carsons S. E. · 1989
8. 10.1007/BF0069029010.1007/BF00690290 ↗
9. 10.1016/0092-8674(92)90600-H10.1016/0092-8674(92)90600-H ↗
10. Zitzmann S. · Cancer Res. · 2002 · 62 · 5139
11. 10.1002/chem.20020430410.1002/chem.200204304 ↗
12. 10.1021/ja972467o10.1021/ja972467o ↗
13. 10.1021/ja038265b10.1021/ja038265b ↗
14. 10.1002/1521-3773(20010316)40:6<1093::AID-ANIE10930>3.0.CO;2-Q10.1002/1521-3773(20010316)40:6<1093::AID-ANIE10930>3.0.CO;2-Q ↗
15. 10.1021/nn502690b10.1021/nn502690b ↗
16. 10.1002/jbm.82028030710.1002/jbm.820280307 ↗
17. 10.1021/bm005584b10.1021/bm005584b ↗
18. 10.1002/1097-4636(20010905)56:3<390::AID-JBM1108>3.0.CO;2-L10.1002/1097-4636(20010905)56:3<390::AID-JBM1108>3.0.CO;2-L ↗
19. 10.1021/ja053648q10.1021/ja053648q ↗
20. 10.1016/j.biomaterials.2005.01.04510.1016/j.biomaterials.2005.01.045 ↗
21. 10.1016/S0142-9612(03)00343-010.1016/S0142-9612(03)00343-0 ↗
22. 10.1098/rsfs.2011.012410.1098/rsfs.2011.0124 ↗
23. 10.1002/anie.20120211810.1002/anie.201202118 ↗
24. 10.1039/C3CS60419E10.1039/C3CS60419E ↗
25. 10.1038/nmat244210.1038/nmat2442 ↗
26. 10.1021/ja401000m10.1021/ja401000m ↗
27. 10.1002/anie.20100585310.1002/anie.201005853 ↗
28. 10.1021/cr030078910.1021/cr0300789 ↗
29. 10.1021/ja711016m10.1021/ja711016m ↗
30. 10.1021/bi035267010.1021/bi0352670 ↗
31. 10.1083/jcb.114.5.108910.1083/jcb.114.5.1089 ↗
32. 10.1021/la503521x10.1021/la503521x ↗
33. 10.1002/adfm.20130241110.1002/adfm.201302411 ↗
34. 10.3390/polym602026410.3390/polym6020264 ↗
35. 10.1371/journal.pone.009187510.1371/journal.pone.0091875 ↗
36. 10.1074/jbc.M110.13939410.1074/jbc.M110.139394 ↗
37. 10.1074/jbc.M113.46984110.1074/jbc.M113.469841 ↗
38. Schor S. L. · Cancer Res. · 2003 · 63 · 8827
39. Schor S. L. · J. Cell Sci. · 1999 · 112 · 387910.1242/jcs.112.22.3879 ↗
40. 10.1074/jbc.M70753220010.1074/jbc.M707532200 ↗
41. 10.1016/j.yexcr.2010.04.00310.1016/j.yexcr.2010.04.003 ↗
42. 10.1002/ijc.2105310.1002/ijc.21053 ↗
43. 10.1002/anie.20080016610.1002/anie.200800166 ↗
44. 10.1073/pnas.93.20.1077510.1073/pnas.93.20.10775 ↗
45. 10.1021/jp972635z10.1021/jp972635z ↗
46. 10.1021/la00041a01510.1021/la00041a015 ↗
47. Palegrosdemange C. · J. Am. Chem. Soc. · 1991 · 12 · 113
48. 10.1021/ja021074910.1021/ja0210749 ↗
49. 10.1021/la034707l10.1021/la034707l ↗
50. The incubation time was selected as an optimal compromise considering the timeframe for the cell adhesion imaging and the subsequent FAK phosphorylation assessment through western blotting.
51. 10.1242/jcs.112.16.267710.1242/jcs.112.16.2677 ↗
52. 10.1038/3501051710.1038/35010517 ↗
53. 10.1023/A:102372502958910.1023/A:1023725029589 ↗
54. 10.1083/jcb.20021211410.1083/jcb.200212114 ↗
55. 10.1016/j.gde.2003.12.00210.1016/j.gde.2003.12.002 ↗
56. 10.1016/j.ceb.2006.08.01110.1016/j.ceb.2006.08.011 ↗
57. 10.1002/adma.20150090010.1002/adma.201500900 ↗
58. 10.1186/1476-4598-10-7510.1186/1476-4598-10-75 ↗
59. 10.1186/bcr336110.1186/bcr3361 ↗
60. 10.1007/s13277-010-0106-910.1007/s13277-010-0106-9 ↗
61. 10.1109/JMEMS.2005.85908710.1109/JMEMS.2005.859087 ↗
62. 10.1016/S0142-9612(99)00165-910.1016/S0142-9612(99)00165-9 ↗
63. 10.1007/s00216-004-2847-z10.1007/s00216-004-2847-z ↗
64. 10.1039/B613349E10.1039/B613349E ↗
65. 10.1016/j.nantod.2009.12.00110.1016/j.nantod.2009.12.001 ↗
66. 10.1016/j.jcis.2014.05.05410.1016/j.jcis.2014.05.054 ↗
67. 10.1186/1471-2407-11-29310.1186/1471-2407-11-293 ↗
68. Lechertier T. · Anticancer Res. · 2004 · 24 · 4011
69. 10.1039/b801394b10.1039/b801394b ↗
70. 10.1242/jcs.07198510.1242/jcs.071985 ↗
71. 10.1038/nmat406210.1038/nmat4062 ↗